3,000 Shares in Axonics, Inc. (NASDAQ:AXNX) Acquired by Murchinson Ltd.

Murchinson Ltd. bought a new stake in Axonics, Inc. (NASDAQ:AXNX) in the third quarter, Holdings Channel.com reports. The institutional investor bought 3,000 shares of the company’s stock, valued at approximately $209,000.

Several other large investors also recently added to or reduced their stakes in the business. Headlands Technologies LLC boosted its holdings in Axonics by 162.1% in the second quarter. Headlands Technologies LLC now owns 2,928 shares of the company’s stock worth $197,000 after purchasing an additional 1,811 shares in the last quarter. Xponance Inc. lifted its position in shares of Axonics by 7.5% in the second quarter. Xponance Inc. now owns 3,231 shares of the company’s stock worth $217,000 after buying an additional 225 shares during the last quarter. Entropy Technologies LP bought a new stake in shares of Axonics during the 3rd quarter worth about $395,000. Mercer Global Advisors Inc. ADV increased its holdings in shares of Axonics by 12.7% during the 2nd quarter. Mercer Global Advisors Inc. ADV now owns 6,981 shares of the company’s stock valued at $469,000 after acquiring an additional 785 shares during the last quarter. Finally, SG Americas Securities LLC raised its stake in shares of Axonics by 379.6% in the 2nd quarter. SG Americas Securities LLC now owns 8,321 shares of the company’s stock valued at $559,000 after acquiring an additional 6,586 shares in the last quarter. 99.48% of the stock is owned by institutional investors.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Axonics in a research report on Friday, November 8th. Eight research analysts have rated the stock with a hold rating, According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and an average target price of $71.00.

Insiders Place Their Bets

In related news, CFO Kari Leigh Keese sold 2,961 shares of the stock in a transaction dated Wednesday, October 2nd. The stock was sold at an average price of $69.41, for a total transaction of $205,523.01. Following the completion of the transaction, the chief financial officer now directly owns 40,362 shares in the company, valued at approximately $2,801,526.42. This trade represents a 6.83 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Company insiders own 1.85% of the company’s stock.

Axonics Stock Up 0.8 %

Shares of NASDAQ:AXNX opened at $70.98 on Wednesday. Axonics, Inc. has a 12 month low of $55.09 and a 12 month high of $71.05. The firm has a market cap of $3.63 billion, a P/E ratio of -591.45 and a beta of 0.82. The company’s 50-day moving average price is $70.36 and its two-hundred day moving average price is $68.90.

About Axonics

Axonics, Inc, a medical technology company, engages in the development and commercialization of novel products for the treatment of bladder and bowel dysfunction. Its sacral neuromodulation (SNM) systems are used to treat patients with overactive bladder (OAB), including urinary urge incontinence and urinary urgency frequency, as well as fecal incontinence (FI) and non-obstructive urinary retention (UR); and rechargeable (R20) and recharge-free (F15) implantable SNM systems that delivers mild electrical pulses to the targeted sacral nerve to restore normal communication to and from the brain to reduce the symptoms of OAB, UR, and FI.